MRKMerck & Co.
$145.27+77% 1Y
$145.27
$80.6152 weeks$156.44
MRK in its own filings
Nothing in MRK's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
491
Events found in the filings · across 3,002 filings · the record starts in 1997
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 15, 2026
Most recent filing · Form 25-NSE
- Record starts
- Mar 21, 1997
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 29, 2026
- Change in certifying accountanthistorical
- 2009-11-04
- Security removed from listing or deregistered5 occurrences · usually a matured note or preferred class, not the common shares
- 2026-10-15
- Material impairment3 occurrences
- 2017-02-23
- SEC comment-letter activity46 occurrences
- 2025-04-28
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 13, 2026The Board appointed Mr. Diaz as a member of both the Audit Committee and the Research Committee of the Board.Director or officer change · Form 8-K
- Aug 4, 2026Merck & Co., Inc., Rahway, N.J., USA Announces.Earnings release · press release
- May 22, 2026On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal …Other event · Form 8-K
- Apr 30, 2026Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical.Earnings release · press release
- Feb 3, 2026& Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results;.Earnings release · press release
- Dec 4, 2025On December 4, 2025, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2029 (the “Floating Rate Notes”), $750,000,000 aggregate principal amount of 3.850% Notes due 2029 (the “2029 Notes”), $1,000,000,000 aggregate principal …Other event · Form 8-K
- Oct 30, 2025Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, General
The closest names by size in the same industry